Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. The study aimed to a...

Full description

Bibliographic Details
Main Authors: Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Domenico Triggiani, Rossella Donghia, Lucilla Crudele, Roberta Rinaldi, Carlo Sabbà, Vincenzo Triggiani, Giovanni De Pergola, Giuseppina Piazzolla
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Nutrients
Subjects:
nonalcoholic fatty liver disease (NAFLD)
liver steatosis
metabolic associated fatty liver disease (MAFLD)
type 2 diabetes
obesity
semaglutide
Online Access:https://www.mdpi.com/2072-6643/14/21/4673

Internet

https://www.mdpi.com/2072-6643/14/21/4673

Similar Items